Home » Market News » DirectorsTalk Highlights » AI, big data to tackle metabolic disease via genetics, behaviour
Frontier IP Group Plc

AI, big data to tackle metabolic disease via genetics, behaviour

Artificial intelligence and big data are poised to address the complexity of metabolic diseases, drawing out specific genetic and environmental factors that can inform discovery and development of new therapies and providing the means to modify behaviours which underlie those conditions.

“These tools are starting to come into play and we are optimistic it will start to yield therapies,” said Iain Wilcox, investment advisor at French venture capital firm Seventure Partners. “Many years have been spent trying to unpick these conditions with limited success. The dream is that AI and big data will start to shed light on genes and environmental factors,” Wilcox told delegates at Biotrinity 2019.

Exscientia is at the forefront of artificial intelligence (AI)-driven drug discovery and design. Frontier IP Group plc (LON:FIPP) as a 5% holding in Exscientia as of 30th June 2016.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.